I am a healthcare professional

Notice


Welcome to MEDICALLY. This website is a non-promotional international resource intended to facilitate transparent scientific exchange regarding developments in medical research and disease management. It is intended for healthcare professionals outside the United Kingdom (UK) and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications and services that are not approved or valid in your jurisdiction. Registration status and prescribing information of medicinal products may differ between countries. Roche and Genentech do not support, endorse or recommend the unapproved use of any compound or service in your jurisdiction, including those discussed on this website.


Please refer to local product information for any medicinal products mentioned. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same. Healthcare professionals outside the US are required to register and log-in to access the full range of content available on this website.


By clicking on one of the healthcare professional buttons below, you acknowledge you have read and understood this message and that you are requesting access to MEDICALLY. If you are not a healthcare professional, please use the other links below to access information relevant to you.


Cookies


We use cookies on this site to enable the site to function properly and to enhance your user experience. Cookies are files stored in your browser, which most websites use to personalize your web experience. Your information will only be used to provide information that is relevant to you. It will not be used for any other purpose. If you wish to restrict or block cookies, which are set on your device, then you can do this through your browser settings.


You can find out more about cookies by browsing our Privacy Policy.

 

For healthcare professionals in Another Country browse medically.roche.com.

Not a healthcare professional? For individuals outside the US, browse Roche's patient website or roche.com. For individuals in the US, browse gene.com.

External site

The link you have selected will take you away from this site to one that is not owned or controlled by Genentech, Inc. Genentech, Inc. makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.

Leave site
Roche and Genentech at

EHA 2025

We will be contributing to topics related to
-
04:30 PM
Duration 60mins Milan, Italy
Mosunetuzumab▼ demonstrates durable clinical benefit in patients (pts) with complete response (CR) and high-risk relapsed/refractory (R/R) follicular lymphoma (FL)
Cheah CY, Barlett NL, Matasar M, Schuster SJ, Assouline S, Sehn LH, Kuruvilla J, Giri P, Shadman M, Ku M, Hess G, Gregory GP, Kim W, Wei MC, Yin S, Sit J, Tracy S, Kwan A, Penuel E, Budde EL
09:45 AM
Duration 15mins Allianz MiCo Milano Convention Centre
Polatuzumab vedotin▼, rituximab, gemcitabine, and oxaliplatin (Pola-R-GemOx) for relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): results from the randomized phase III POLARGO trial
Matasar M, Li Z, Vassilakopoulos T, Sancho JM, Viardot A, McMillan, A, Dal MS, Pereira J, Kim JS, Qiu L, Batlevi CL, Ibrahim R, Hernandez J, McCall B, Jiang Y, Yan M, Harris W, Musick L, Haioun C
03:00 PM
Duration 15mins Allianz MiCo Milano Convention Centre
MorningSun: open-label phase II trial of the efficacy and safety of subcutaneous mosunetuzumab▼ (Mosun SC) as frontline (1L) treatment in symptomatic patients with marginal zone lymphoma (MZL)
Burke JM, Tun AM, Villasboas J, Budde LE, Gandhi M, Graff T, Jani P, Biondo JML, Wu M, Farighi R, Mun Y, Lin T, Munoz J, Flinn I
04:30 PM
Duration 60mins Milan, Italy
Glofitamab▼ plus gemcitabine and oxaliplatin (Glofit-GemOx) in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): 2-year follow-up of STARGLO
Gregory GP, Ku M, Hertzberg M, Fox CP, Herbaux C, Huang H-Q, Yoon DH, Kim WS, Zhang H, Abdulhaq H, Townsend W, Mulvihill E, Orellana-Noia V, Ta R, Huang H, Kallemeijn MJ, Belousov A, Bottos A, Lundberg L, Abramson JS
Duration 60mins Milan, Italy
Impact of tumor burden and prior venetoclax treatment on mosunetuzumab▼-mediated tumour control in relapsed/refractory CLL
Jin HY, Barrett K, Schroeder A, Ho H, Breton V, Penuel E, Kesavan M, Breuleux M, Sugidono M, Opat S, Tausch E
Duration 60mins Milan, Italy
Fixed-duration subcutaneous mosunetuzumab▼ demonstrates clinically relevant efficacy in patients with relapsed/refractory follicular lymphoma with high-risk features: pivotal phase II study update
Hess G, Sehn LH, Budde EL, Assouline S, Giri P, Kuruvilla J, Schuster SJ, Yoon SS, Fay K, Dreyling M, Guitierrez NC, Cybulski E, Sabalvaro F, Penuel E, Tracy S, Kuruvilla D, Chen J, Wiebking V, Wei MC, Bartlett NL
Coming soon